Aquaporin (AQP) H1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2025 earnings summary
23 Nov, 2025Executive summary
New CEO appointed, leading the company through a period of transition and strategic review.
Completed successful technology trials in Singapore, achieving up to 20% energy savings, and secured new pilot contracts in Dublin and the US.
Strengthened presence in China, South and Latin America, and Europe for wastewater recycling and market expansion.
Revenue for H1 2025 was DKK 9.1 million, down from DKK 29.2 million year-over-year, mainly due to timing shifts in Residential Drinking Water demand.
Strategic review initiated to explore capital-raising options for operations beyond 2025.
Financial highlights
Revenue for H1 2025 was DKK 9.1 million, down from DKK 29.2 million year-over-year.
EBITDA before special items was a loss of DKK 28 million, improved from a loss of DKK 33.5 million last year.
Cash and cash equivalents at end of June 2025 were DKK 29.4 million, compared to DKK 103.5 million a year earlier and DKK 77.3 million at end-2024.
Net loss after tax was DKK 38.8 million, compared to DKK 42.6 million in the prior year period.
EBIT before special items was a loss of DKK 36.7 million for H1 2025, compared to DKK 42.2 million for H1 2024.
Outlook and guidance
Revenue guidance for 2025 lowered to DKK 40–50 million from DKK 60–80 million due to lower order inflow and delays.
EBITDA guidance for 2025 remains unchanged at a loss of DKK 45–55 million.
Majority of revenue expected in H2 2025, with a more balanced contribution across business lines.
Revenue expected to be distributed evenly across Residential Drinking Water, Industrial Water, and Forward Osmosis Market Development segments.
Strategic review underway to secure additional capital for operations beyond 2025.
Latest events from Aquaporin
- 44% revenue growth, improved margins, and 2024 outlook reaffirmed after capital raise.AQP
H1 202423 Jan 2026 - 2024 revenue fell 32% but Industrial Water surged 192%; rights issue and incentives below target.AQP
H2 202423 Dec 2025 - Q3 revenue rose 14% year-on-year as capital-raising efforts intensify for future growth.AQP
Q3 2025 TU13 Nov 2025 - Order delays impacted Q3 revenue, but new partnerships and innovations support 2025 growth.AQP
Q3 2024 TU13 Jun 2025 - Q1 revenue declined but guidance held as orderbook and strategic growth support 2025 outlook.AQP
Q1 2025 TU6 Jun 2025